Related Experiment Video
Updated: Jun 1, 2025
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Improving systemic delivery of oncolytic virus by cellular carriers
Ziyi Peng1, Muhammad Kalim1, Yong Lu1
1Houston Methodist Cancer Center/Weill Cornell Medicine, Houston, TX 77030, USA.
Abstract:
Oncolytic virotherapy (OVT) is a promising option for cancer treatment. OVT involves selective oncolytic virus (OV) replication within cancer cells, which triggers anti-tumor responses and immunostimulation. Despite promising potential, OVT faces critical challenges, including insufficient tumor-specific targeting, which results in limited tumor penetration and variability in therapeutic efficacy. These challenges are particularly pronounced in solid tumors with complex microenvironments and heterogeneous vascularization. A comprehensive research program is currently underway to develop and refine innovative delivery methods to address these issues to enhance OVT precision and efficacy. A principal area of investigation is the utilization of cellular carriers to enhance the delivery and distribution of OVs within tumor microenvironments, thereby optimizing immune system activation and maximizing anti-tumor effects. This review offers a comprehensive overview of the current strategies that are being used to enhance the delivery of OVs via cellular carriers with the goal of improving the clinical impact of OVT in cancer therapy.
Insights
Oncolytic virotherapy (OVT) uses viruses to target cancer cells, but delivery to solid tumors is challenging. Cellular carriers are being explored to improve oncolytic virus (OV) delivery and enhance cancer treatment efficacy.
Area of Science:
- Oncology
- Virology
- Immunotherapy
Background:
- Oncolytic virotherapy (OVT) shows promise for cancer treatment by selectively replicating oncolytic viruses (OVs) in cancer cells, stimulating anti-tumor immune responses.
- Key challenges in OVT include insufficient tumor-specific targeting, limited tumor penetration, and variable efficacy, especially in complex solid tumor microenvironments.
Purpose of the Study:
- To review current strategies for enhancing oncolytic virus (OV) delivery using cellular carriers.
- To explore how cellular carriers can improve OV distribution within tumor microenvironments for optimized immune activation and anti-tumor effects.
Main Methods:
- Review of existing research on cellular carrier-mediated delivery of oncolytic viruses (OVs).
- Analysis of strategies aimed at improving OV targeting, penetration, and efficacy within solid tumors.
Main Results:
- Cellular carriers show potential for improving the delivery and distribution of OVs in tumor microenvironments.
- Enhanced delivery via cellular carriers may optimize immune system activation and maximize anti-tumor effects.
Conclusions:
- Improving OV delivery through cellular carriers is crucial for enhancing the clinical impact of oncolytic virotherapy (OVT).
- Further research into cellular carrier strategies is needed to overcome OVT challenges and improve cancer treatment outcomes.
Related Concept Videos
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...